DRUG

curcumin

Dietary supplement; multiple investigational uses

88 hypotheses across 10 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

curcumin appears in hypotheses across 10 disease domains: ALS, Alzheimer, Depression, Epilepsy, Glioblastoma, Inflammatory bowel disease, Multiple sclerosis, Pancreatic cancer, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: STAT3, BDNF, caspase-3, TDP-43, GSK3β, NRF2.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for curcumin

ALS 35

Mediator Outcome Score Tier Lit. status Trial
TDP-43 ALS 0.614 High reproduces known completed Case study →
TDP-43 FTLD 0.312 High partial evidence none
TDP-43 neurodegeneration 0.269 Mid reproduces known none
TDP-43 Frontotemporal dementia 0.269 Mid partial evidence none
TDP-43 neurodegenerative diseases 0.269 Mid reproduces known active
total cholesterol ALS 0.269 Mid reproduces known completed
TDP-43 motor deficits 0.269 Mid reproduces known none
TDP-43 neurodegeneration 0.269 Mid reproduces known none
TDP-43 neuronal dysfunction 0.269 Mid reproduces known none
TDP-43 neurodegenerative diseases 0.269 Mid reproduces known completed
TDP-43 cell viability 0.208 Mid reproduces known none
TDP-43 growth cone size 0.208 Mid novel signal none
TDP-43 axonal transport 0.208 Mid partial evidence none
TDP-43 Perry syndrome 0.208 Mid novel signal none
TDP-43 RNA instability 0.208 Mid novel signal none
TDP-43 harmful R-loop accumulation 0.208 Mid novel signal none
TDP-43 skeletal muscle atrophy 0.208 Mid partial evidence preclinical only
TDP-43 pathological phenotypes 0.208 Mid novel signal none
TDP-43 motor neuron degeneration 0.208 Mid novel signal none
TDP-43 axon wrapping 0.208 Mid novel signal none
TDP-43 sporadic amyotrophic lateral sclerosis 0.208 Mid novel signal none
TDP-43 behavioural variant frontotemporal dementia 0.208 Mid novel signal none
TDP-43 memory loss 0.208 Mid reproduces known completed
amyloid-beta metabolic dyshomeostasis 0.208 Mid novel signal none
NRF2 neurodegenerative processes 0.208 Mid reproduces known none
total cholesterol earlier age at onset of ALS 0.208 Mid novel signal none
amyloid-beta Parkinson's disease 0.208 Mid reproduces known completed
amyloid-beta cardiovascular disease 0.208 Mid reproduces known active
TDP-43 organelle defects 0.208 Mid novel signal none
TDP-43 DNA damage 0.208 Mid reproduces known completed
TDP-43 axonal translation 0.208 Mid novel signal none
TDP-43 presynaptic dysfunction 0.208 Mid novel signal none
TDP-43 cell cycle arrest at G2/M phase 0.208 Mid novel signal none
GSK3β CTE-ALS 0.208 Mid novel signal none
TDP-43 neurotoxicity 0.208 Mid reproduces known none

Alzheimer 2

Mediator Outcome Score Tier Lit. status Trial
STAT3 cognitive deficits 0.312 High reproduces known active
caspase-3 dendritic spine loss 0.208 Mid partial evidence none

Depression 16

Mediator Outcome Score Tier Lit. status Trial
BDNF schizophrenia 0.312 High reproduces known completed
BDNF depression severity 0.269 Mid partial evidence none
BDNF bipolar disorder 0.269 Mid reproduces known completed
GSK3β mood disorders 0.208 Mid reproduces known completed
BDNF improvement in depressive symptoms 0.208 Mid novel signal none
BDNF suicide risk 0.208 Mid novel signal none
BDNF major depression 0.208 Mid reproduces known completed
BDNF anhedonia 0.208 Mid partial evidence none
BDNF remission 0.208 Mid reproduces known completed
BDNF depressive disorder 0.208 Mid reproduces known completed
BDNF MDD 0.208 Mid reproduces known completed
BDNF visuospatial ability 0.208 Mid novel signal none
BDNF remission 0.208 Mid reproduces known completed
BDNF depressive symptoms 0.208 Mid reproduces known completed
BDNF depression severity (HAMD-17 score) 0.208 Mid novel signal none
BDNF language function 0.208 Mid novel signal none

Epilepsy 13

Mediator Outcome Score Tier Lit. status Trial
STAT3 GABAergic neuron loss 0.312 High novel signal none
STAT3 persistence of reactive glial states 0.312 High novel signal none
STAT3 general cell loss 0.312 High novel signal none
STAT3 imprinting of epileptic activity patterns 0.312 High novel signal none
amyloid beta cerebral amyloid angiopathy-related inflammation 0.269 Mid novel signal none
amyloid beta seizure susceptibility 0.269 Mid novel signal none
TDP-43 hippocampal sclerosis 0.269 Mid novel signal none
BDNF seizure frequency 0.269 Mid partial evidence none
MGMT progression-free survival 0.208 Mid reproduces known none
MGMT seizure reduction 0.208 Mid novel signal none
EZH2 seizure burden 0.208 Mid novel signal none
caspase-3 drug-resistant epilepsy 0.208 Mid partial evidence none
EZH2 epileptogenesis 0.208 Mid reproduces known none

Glioblastoma 4

Mediator Outcome Score Tier Lit. status Trial
STAT3 glioblastoma progression 0.312 High partial evidence none
MAPK pathway pediatric diffuse low-grade glioma 0.269 Mid novel signal none
FOXP3 poor prognosis 0.208 Mid reproduces known none
Foxp3 poor prognosis 0.208 Mid reproduces known none

Inflammatory bowel disease 1

Mediator Outcome Score Tier Lit. status Trial
BDNF cell viability 0.208 Mid reproduces known none

Multiple sclerosis 4

Mediator Outcome Score Tier Lit. status Trial
NRF2 Hashimoto's thyroiditis 0.208 Mid partial evidence preclinical only
Nrf2 visual function 0.208 Mid reproduces known completed
NLRP3 inflammasome activation acute lung injury 0.208 Mid reproduces known none
Nrf2 retinal ganglion cell survival 0.208 Mid novel signal none

Pancreatic cancer 9

Mediator Outcome Score Tier Lit. status Trial
STAT3 pancreatic ductal adenocarcinoma 0.312 High reproduces known none
STAT3 pancreatic cancer 0.312 High reproduces known completed
STAT3 drug resistance 0.312 High reproduces known none
STAT3 immune escape 0.312 High reproduces known none
NOTCH signaling pathway pancreatic cancer 0.208 Mid reproduces known completed
caspase-3 inflammatory peritumoral infiltration 0.208 Mid novel signal none
Hes1 poor prognosis 0.208 Mid reproduces known none
Foxp3 good prognosis 0.208 Mid partial evidence none
Hes1 pancreatic regeneration 0.208 Mid partial evidence none

Rheumatoid arthritis 2

Mediator Outcome Score Tier Lit. status Trial
STAT3 prurigo nodularis 0.416 High novel signal none
NLRP3 inflammasome activation inflammatory arthritis 0.208 Mid partial evidence active

Type 2 diabetes 2

Mediator Outcome Score Tier Lit. status Trial
BDNF diabetes risk factors 0.208 Mid novel signal none
NFKB1 diabetes progression 0.208 Mid partial evidence none

Clinical trials

200 registered trials for curcumin

Source: ClinicalTrials.gov

← All drugs